Notizie AIOM – anno XV – Pagina 67

5 Maggio 2017

FDA Approves Durvalumab for Bladder Cancer

May 1, 2017 - The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have ...
Leggi tutto

5 Maggio 2017

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs overall survival compared with no prophylactic cranial irradiation in patients with extensive-disease small-cell lung ...
Leggi tutto

5 Maggio 2017

Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

Burnout in health care professionals could have serious negative consequences on quality of patient care, professional satisfaction and personal life. Our aim was to investigate the burnout prevalence, work and lifestyle factors potentially affecting burnout amongst European ...
Leggi tutto

5 Maggio 2017

3 maggio 2017 – Registri AIFA: l’Agenzia fornisce informazioni sui dati dei trattamenti con i nuovi farmaci per la cura dell’epatite C

5 Maggio 2017

4 maggio 2017 – FDA approva un nuovo trattamento di combinazione per la leucemia mieloide acuta

5 Maggio 2017

ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding

May 2, 2017 - On May 1, Congress announced a bipartisan 2017 budget deal that contains a $2 billion increase in medical research funding for the National Institutes of Health (NIH), including $475 million more for the National Cancer Institute. The budget also maintains ...
Leggi tutto

5 Maggio 2017

ASCO/CCO Clinical Practice Guideline Update: Adjuvant Therapy for Resected Non–Small Cell Lung Cancers

May 2, 2017 - As reported in the Journal of Clinical Oncology by Mark G. Kris, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO and Cancer Care Ontario (CCO) have issued an update to the ASCO/CCO clinical practice guideline on adjuvant systemic therapy ...
Leggi tutto

5 Maggio 2017

EU Approves Daratumumab Triplets for Myeloma

May 1, 2017 - The European Commission (EC) has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy, based primarily on findings ...
Leggi tutto

5 Maggio 2017

European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy

May 2, 2017 - On April 28, the European Commission approved nivolumab as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology ...
Leggi tutto

5 Maggio 2017

Concept paper MABS2

Il Sole 24ore Sanità ha pubblicato il numero monografico dedicato alle "Opportunità e sfide dei biotecnologici e dei biosimilari nelle patologie linfoproliferative e reumatologiche. Integrare le variabili regolatorie, gli aspetti clinici e la sostenibilità ...
Leggi tutto

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Notizie AIOM – anno XV

FDA Approves Durvalumab for Bladder Cancer

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

3 maggio 2017 – Registri AIFA: l’Agenzia fornisce informazioni sui dati dei trattamenti con i nuovi farmaci per la cura dell’epatite C

4 maggio 2017 – FDA approva un nuovo trattamento di combinazione per la leucemia mieloide acuta

ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding

ASCO/CCO Clinical Practice Guideline Update: Adjuvant Therapy for Resected Non–Small Cell Lung Cancers

EU Approves Daratumumab Triplets for Myeloma

European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy

Concept paper MABS2